Document is current
Any future updates will be listed below
-
Authors
Karlsson, Leo https://orcid.org/0009-0009-4880-6496
Ciccolini, Joseph https://orcid.org/0000-0003-1733-3410
ter Heine, Rob https://orcid.org/0000-0003-2185-8201
Centanni, Maddalena https://orcid.org/0000-0001-6594-9813
-
Funding
Funding for this research was provided by:
Cancerfonden (23 2921 Pj)
Uppsala University
- License Information
-
More Information
Article History
Received: 19 April 2025
Accepted: 11 August 2025
First Online: 10 September 2025
Declarations
:
: MC, LK, JC, and RH wrote the manuscript. MC and LK designed and performed the research. MC, LK, and RH analyzed the data.
: Data will be made available on reasonable request.
: Rob ter Heine has received research funding from Stichting Treatmeds to investigate alternative dosing regimens for pembrolizumab. All other authors have no potential conflicts of interest with respect to the research, authorship, and/or publication of this manuscript.
